News

TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children

Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011 Apr 2. [Epub ahead of print]

This week, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. In previous research, combining IPT and ART showed a 76% reduction in risk of TB in HIV-infected adults compared to those not on either treatment.

The study found that that IPT combined with ART greatly reduced the risk of TB significantly compared to children receiving only IPT or only ART. This finding could have implications for policy recommendations for children on ART. The screening of children for active TB disease is important to reduce the emergence of resistance. Other interesting points include:

  • Infants with HIV have a 24-fold higher risk of getting TB than infants without HIV infection.
  • Children with HIV and TB have a greater risk of more severe disease, progressing more rapidly to disease, and death.
  • The finding from the study, which took place in South Africa, may not apply to low TB prevalence settings.
  • For the analysis, Cox proportional hazards regression was used and hazard ratios generated.
  • Since young children are more likely to develop disease from a primary infection and not reactivation of latent infections, IPT may help contain primary infection in children receiving ART.

Additional TB R&D News:

Multi-drug Resistant Childhood Tuberculosis

Pharmacokinetics of Anti-tuberculosis Drugs in Children

Management of Tuberculosis in Children and New Treatment Options

India, Spain JV biotech plant inaugurated

New Database to Help Track Quality of Medicines in Global Markets


More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...